Table of Contents

Chapter 1 1
1.1 Atherosclerosis 1
1.2 Current Treatment 3
1.3 Gene Delivery for Atherosclerosis: Current Status 3
1.4 Targeting of genes. 4
1.4.1 APO A1. 4
1.4.2 APOE 5
1.4.3 SR-BI. 5
1.4.4 Lecithin-cholesterol acyltransferase (LCAT). 6
1.4.5 Cholesteryl ester transfer protein (CETP). 6
1.5 Gene Delivery Vectors.. 8
1.5.1 Liposome Based Gene Delivery. 8
1.5.2 Lipoplexes and Polyplexes 8
1.6 Targeting Strategies to Hepatic cells and Endothelial Cells 9
1.7 Aim of the Work.. 12
1.8 Rationale of the Study 13
1.9 Hypothesis.. 14
1.10 Objectives.. 14
1.11 Plan of Work 15
1.12 Proposed Strategy (Graphical overview) 15
1.13 References.. 18

Chapter 2 23
2.1 Atherosclerosis 23
2.1.1 Pathophysiology of the disease 25
2.1.2 Atherosclerosis treatment and its management 29
2.2 Gene therapy as an approach for atherosclerosis – Current perspective 30
2.2.1 APO A1 31
2.2.2 APO E 32
2.2.3 SR-BI 33
2.2.4 Lecithin-cholesterol acyltransferase (LCAT) 33
2.2.5 Cholesteryl ester transfer protein (CETP) 34
2.3 Lipoplexes as gene delivery vector 36
2.4. Systemic gene delivery using lipid non-viral vectors - lipoplexes and other lipidic systems 38
2.4.1 Importance of Lipid envelope systems as nucleic acid delivery vectors 41
2.4.2 Structural features of lipid envelope systems of siRNA 47
2.4.3 Overcoming challenges 50
2.4.4 Structural features of complex 57
2.4.5 Cationic lipid:nucleic acid N/P ratio 58
2.4.6 Lipid composition of complex 59
2.5 Emerging Strategies for gene delivery 61
2.6 The way forward 64
2.7 Targeting liver cells 65
2.8 References 69

Chapter 3 90
3.1 Introduction 90
3.2 Analytical methods used for quantification of pDNA 90
3.2.1 UV Spectrophotometric Analysis of DNA 90
3.2.1.1 Material 91
3.2.1.2 Method 91
3.2.1.3 Results and discussion 91
3.2.2 Spectrofluorometric method: Quantifluor 94
3.2.2.1 Protocol for Quantitating dsDNA 94
3.2.2.2 Results and Discussion 94
3.2.3 Gel Electrophoresis of pDNA 96
3.2.2.1 Material 97
3.2.2.2 Method 98
3.2.2.3. Results and Discussion 98
3.3 Analytical methods used for characterization of lipids 101
3.3.1 TNBS assay 101
3.3.1.1 Materials 102
3.3.1.2 Method 102
3.3.1.3 Results and discussion 103
3.3.2 Sakaguchi assay 107
3.3.2.1 Materials 107
3.3.2.2 Method 108
3.3.2.3 Results and discussion 108
3.4 References 110

Chapter 4 111
4.1 Selection of pDNAs and their properties 111
4.1.1 Rationale for selection of ApoE3 gene. 111
4.1.2 Properties of ApoE pDNA and protein 113
4.1.2.1 Vector map and pDNA description 113
4.1.2.2 pCMV / ampicillin plasmid complete sequence 114
4.1.2.3 ApoE3 amino acid sequence 115
4.1.2.4 Cloning sites/restriction digestion sites 115
4.1.3 Rationale for selection of eGFP gene 115
4.1.4 Properties of eGFP gene 115
4.1.4.1 Vector map and pDNA description 116
4.1.4.2 pCDNA3/EGFP plasmid complete sequence 116
4.1.4.3 eGFP amino acid sequence 118
4.2 Transformation of pDNA 119
4.2.1 Transformation of competent E. coli using magnesium chloride 119
4.2.1.1 Material 119
4.2.1.2 Method 121
4.2.1.3 Result & Discussion 122
4.2.2. Isolation and purification of plasmid DNA 123
4.2.2.1 Material 126
4.2.2.2 Method 127
4.2.2.3 Result & Discussion 129
4.3 Plasmid Digestion 130
4.3.1 Materials 130
4.3.2 Method 130
4.3.3 Result & Discussion 131
4.3 References 132

Chapter 5 134
5.1 Introduction 134
5.2 Materials and Methods 134
5.2.1 Synthesis of modified lipids 134
5.2.2 Physicochemical characteristics of the lipids and pH titration study: 138
5.3 Results and discussion 138
5.4 References 147

Chapter 6 148
6.1 Development of lipoplexes: 148
6.1.1 Stearyl amine 148
6.1.2 DOTAP 149
6.1.3 Synthesized lipids 150
6.2 Preparation of liposomes 150
6.2.1 Preparation of Stearyl amine-DSPE based liposomes 150
6.2.2 Preparation of lipoplexes: 150
6.2.3 Optimization of Parameters 151
6.2.4 Lyophilization of Lipoplexes 151
6.2.5 Physicochemical characterization of liposomes and lipoplexes 153
6.2.5.1 Complexation Efficiency 153
i. EtBr intercalation assay using gel electrophoresis 153
ii. UV spectrophotometric determination after Centrifugation 153
ii. Spectrofluorometric determination after Centrifugation 153
6.2.5.2 Particle size and zeta potential analysis. 154
6.2.5.3 Cryo-Transmission Electron Microscopy (Cryo-TEM) 154
6.2.5.4 Assay 155
6.2.5.5 Residual Water content: 156
6.2.5.6 Statistical Analysis 156
6.3 Results and Discussion 157
6.3.1 Preparation of stearyl amine-DSPE based liposomes 157
6.3.1.1 Optimization of process parameters 157
6.3.1.2 Optimization of formulation components 160
6.3.1.3 Preliminary Screening of Formulations: DSPE lipid incorporated 169
6.3.2 Preparation of DSPE based liposomes 169
6.3.2.1 Formulation Optimization using DOE 178
6.3.2.2 Preparation of liposomes of different modified lipids 204
6.3.3 Preparation of lipoplexes 207
6.3.3.1 Optimization of Process Parameters 207
6.3.3.2 Optimization of Formulation Parameters 214
6.3.3.3 Physicochemical characterization of the lipoplexes 222
6.3.4 Lyophilization of lipoplexes 226
6.4 References 230

Chapter 7 232
7.1 *In vitro* physicochemical characterization 232
7.2 Stability of lipoplexes in presence of electrolyte (NaCl) 232
7.2.1 Method 233
7.2.2 Results and Discussion 234
7.3 Serum Stability Study 242
7.3.1 Methods 242
7.3.2 Result and discussion 243
7.4 References 248

Chapter 8 250
8.1 Introduction 250
8.2 Materials and Instruments 251
8.3 Methods 252
General Methods and Preparations 252
8.4 Cytotoxicity studies 253
8.4.1 Haemolysis Study 254
8.4.1.1 Method 254
8.4.1.2 Results and Discussion 255
8.4.2 MTT assay - on HEPG2 cells 257
8.4.2.2 Methods 258
8.4.2.3 Results and Discussion 263
8.5 GFP expression studies 268
8.5.1 Flow cytometry 268
8.5.1.1 Method 269
8.5.1.2 Results and discussion: 270
8.5.2 Confocal microscopy 274
8.5.2.1 Method 274
8.5.2.2 Results and discussion: 275
8.6 References 279

Chapter 9 281
9.1 Development and evaluation of targeted lipoplexes 281
9.1.1 Preparation of ligand anchored cationic liposomes containing modified lipids: 281
9.1.2: Preparation of ligand anchored cationic liposomes: 281
9.2 References 288

Chapter 10 289
10.1. Acute Toxicity Study 289
10.1.1 Method 290
10.1.1.1 Selection of animals species *290*
10.1.1.2. Housing and feeding conditions *290*
10.1.1.3. Preparation of animals *290*
10.1.1.4. Preparation of doses *291*
10.1.1.5. Procedures *291*
10.1.2 Results and discussion 293
10.2 *In vivo* performance study 296
10.2.1 Diet induced atherogenesis 296
10.2.1.1 Method *297*
10.2.2 Estimation of total cholesterol: 298
10.2.3 Estimation of HDL cholesterol: 299
10.2.4 Estimation of Triglycerides: 301
10.2.5 Estimation of LDL Cholesterol: 302
10.2.6 Histopathology of atherosclerotic lesions: 302
10.2.7 Results and discussion: 303
10.3 References 307

Chapter 11 309
11.1 Stability Studies 309
11.1.1 Method 310
11.1.2 Results and discussion 310
11.2 References 313

Chapter 12 315
Summary and Conclusion: 315